Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers

Respirology

Volumn 19, Issue 5, 2014, Pages 707-713

  Dai, Huaping ^a,b   Liu, Jianqun ^a,b,c   Liang, Lirong ^a,b   Ban, Chengjun ^a,b   Jiang, Jing ^c   Liu, Yan ^a,b   Ye, Qiao ^a,b   Wang, Chen ^b,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Respiratory Medicine   (China)

^c Huaishuling Branch of Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

carbohydrate antigen 19 9; carcinoembryonic antigen; idiopathic pulmonary fibrosis; interstitial lung disease; lung cancer

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; NEURON SPECIFIC ENOLASE; ENOLASE; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT DISEASE; SENSITIVITY AND SPECIFICITY; SMOKING; AGED; BLOOD; COMPARATIVE STUDY; COMPLICATION; LUNG NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

AGED; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903129056     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12317     Document Type: Article

References (28)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002; 165: 277-304.
2. Sverzellati N, Guerci L, Randi G, Calabro E, La Vecchia C, Marchiano A, Pesci A, Zompatori M, Pastorino U,. Interstitial lung diseases in a lung cancer screening trial. Eur. Respir. J. 2011; 38: 392-400.
3. Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K,. Association of malignancy with diseases causing interstitial pulmonary changes. Chest 2002; 121: 1278-1289. (Pubitemid 34280454)
4. Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P,. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010; 65: 70-76.
5. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R,. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir. Med. 2007; 101: 2534-2540. (Pubitemid 47618391)
6. Hubbard R, Venn A, Lewis S, Britton J,. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000; 161: 5-8. (Pubitemid 30055895)
7. Munakata M, Asakawa M, Hamma Y, Kawakami Y,. Present status of idiopathic interstitial pneumonia-from epidemiology to etiology. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32 (Suppl.): 187-192.
8. Takeuchi E, Yamaguchi T, Mori M, Tanaka S, Nakagawa M, Yokota S, Nishikawa H, Noma K, Itoh M, Ogura T,. Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34: 653-658.
9. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T,. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol. Int. 2001; 21: 106-111. (Pubitemid 33071192)
10. Vancheri C, Failla M, Crimi N, Raghu G,. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010; 35: 496-504.
11. Shiota Y, Furuya K, Kitade M, Ueda N,. CEA and CA19-9 in BALF from patients with idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27: 887-893. (Pubitemid 19240788)
12. Obayashi Y, Fujita J, Nishiyama T, Yoshinouchi T, Kamei T, Yamadori I, Hojo S, Ohtsuki Y, Hirashima M, Takahara J,. Role of carbohydrate antigens sialyl Lewis (a) (CA19-9) in bronchoalveolar lavage in patients with pulmonary fibrosis. Respiration 2000; 67: 146-152. (Pubitemid 30193086)
13. Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, Pontisso P, Saetta M, Valente M, Rea F, Perissinotto E, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax 2008; 63: 795-802.
14. Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, Sekizawa K,. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 2003; 123: 2001-2006. (Pubitemid 36706725)
15. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N,. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am. J. Respir. Crit. Care Med. 2002; 165: 378-381. (Pubitemid 34118512)
16. Rusanov V, Kramer MR, Raviv Y, Medalion B, Guber A, Shitrit D,. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest 2012; 141: 1047-1054.
17. Wells AU, Hirani N,. Interstitial lung disease guidelines: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: 1-58.
18. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, Ramirez J, Filella X,. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008; 29: 371-380.
19. Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, Felip E,. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin. Lung Cancer 2011; 12: 172-179.
20. Takamochi K, Nagai K, Suzuki K, Yoshida J, Ohde Y, Nishiwaki Y,. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 2000; 117: 1577-1582. (Pubitemid 30413347)
21. Sawabata N, Maeda H, Yokota S, Takeda S, Koma M, Tokunaga T, Ito M,. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis. Cancer 2004; 101: 803-809. (Pubitemid 39030938)
22. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM,. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002; 69: 25-29. (Pubitemid 34158384)
23. Diez M, Torres A, Maestro ML, Ortega MD, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL,. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br. J. Cancer 1996; 73: 1248-1254. (Pubitemid 26162341)
24. Ando S, Kimura H, Iwai N, Yamamoto N, Iida T,. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. Anticancer Res. 2003; 23: 2869-2874. (Pubitemid 36969825)
25. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M,. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107: 2842-2849. (Pubitemid 44937038)
26. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L,. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem. 2002; 48: 1931-1937. (Pubitemid 35222751)
27. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A,. Increased risk for cancer following sarcoidosis. Am. J. Respir. Crit. Care Med. 1999; 160: 1668-1672.
28. Hirakata Y, Kobayashi J, Sugama Y, Kitamura S,. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur. Respir. J. 1995; 8: 689-696.